..., Book Reviews 815 however, he has a genuine market to attack. A thriving international trade in plasma-derived blood products has developed since The Gift Relationship was published in 1970. Hagen condemns this trade, but seems unpersuaded by his own arguments. Appropriately so...

... at www.hhs.gov/bloodsafety/summaries/sumaug97.html . ———. 1998 . Transcript of meeting held 27–28 August . Available on-line at www.hhs.gov/bloodsafety/transcripts/19980928.html . American Blood Resources Association (ABRA) (now the Plasma Protein Therapeutics Association [PPTA]). 2000 . Plasma...

... name Operation Warp Speed (Slaoui and Hepburn 2020), focused on subsidizing and facilitating the testing and production of COVID-19 vaccines. 4. Pressure Upon the FDA and the Convalescent Plasma Authorization. The Trump Administration s pressure on the FDA reached new levels and broke new barriers...

.../ . Harris Richard . 2020 . “ FDA's Hahn Apologizes for Overselling Plasma's Benefits as a COVID-19 Treatment .” NPR , August 25 . https://www.npr.org/sections/health-shots/2020/08/25/905792261/fdas-hahn-apologizes-for-overselling-plasmas-benefits-as-a-covid-19-treatment . Hayes Michael J...

... the Ad Hoc Clearinghouse Issues Study Committee; Ad Hoc Committee on Plasma and Plasma Supply; Committee for Commonality in Blood Banking Automa- tion; Committee on Utilization of Blood and Blood Components; Task Force on a National Blood Data Center; Task Force on Donor Recruitment...

... in Stone's book: a broad set of experts interrogated, studied, and refuted the earlier claims, after which the authorization was ignominiously withdrawn (Thomson and Nachlis 2020 ). Or take the FDA's August 2020 authorization announcement for convalescent plasma, which involved the agency's commissioner...

...: The Case of Voluntary Blood Donorship. Journal of Social Policy 10 : 53 -79. London , P. , and B. M. Hemphill. 1965 . The Motivations of Blood Donors. Transfusion 14 : 559 -68. National Institutes of Health. 1986 . The Impact of Routine HTLV-1V Antibody Testing of Blood and Plasma Donors...

... . Healthy Incentives Pilot (HIP) Interim Report . Alexandria, VA : USDA . www.fns.usda.gov/sites/default/files/HIP_Interim.pdf . Vesper H. W. , Kuiper H. C. , Mirel L. B. , Johnson C. L. , and Pirkle J. L. 2012 . “ Levels of Plasma Trans-Fatty Acids in non-Hispanic...

... approach. Notably, controversies in early to mid-2020 over the Emergency Use Authorizations (EUAs) for some COVID-19 therapeutics, including hydroxychloroquine, remdesivir, and convalescent plasma, drew criticism that there was insufficient data to support the safety and efficacy of the authorizations...

... how the latter could not have adjusted their behavior to avoid exposure to AIDS; without saying as much, they implied that gay men could have. A CBS story from 26 February 1983 was typical in this regard. Anchor Bob Schieffer began, “Some doctors suspect that blood banks and plasma...

... in “Irreplaceable” drugs, drugs used to treat 30 conditions selected chronic and compassionate use drugs plasma substitutes, tetanus drugs, and others. conditions medical The 30 chronic nonapproved drug if it is designed to treat thea condition for which existing alternative treatment...

... are producing vaccines, and very few licensed firms pose a credible threat of entry. 5. Biological agents include bacterial and viral vaccines, antigens, antitoxins, toxoids, and allogenic extracts as well as sera, plasma, and other blood derivatives for human use. Table 1 Research and Development...

.... Journal of Personality and Social Psychology 39 ( 5 ): 977 -90. Lederman , R. P. , E. Lederman, B. Work, and D. McCann. 1978 . The Relationship of Maternal Anxiety, Plasma Catecholamines, and Plama Cortisol to Progress in Labor. American Journal of Obstetrics and Gynecology 132 ( 5 ): 495...

... market and the blood plasma market, innovation fails to correlate with how collection was organized. Private and public actors, as well as for-profit and nonprofit, attempted to slow innovation in different countries. Nor do the activities of these organizations correlate with polit- ical...

... HIV-infected former plasma donors. The Global Fund's technical review panel rejected the proposal, holding that the government did not show enough “political commitment” (i.e., it did not provide enough of its own financial resources to implement the project). While many Chinese officials involved...

... under similar conditions in an appropriately designed study” (12 CFR 320.1 2015). In summary, the FDA moved from product data to clinical data over the space of thirty years, and all bioequivalence and biosimilarity studies are today carried out with clinical data: hematological tests using plasma...

... sales” (Steinbrook 1981). However, the fundamental rea- son for the shift away from the transfer of blood by sales-even though blood plasma and some blood products are still sold-was not widespread moral re- vulsion, but rather cogent arguments that the commercial system in blood...

...). A European regulatory system for the safety of blood and plasma products was established (Farrell 2006); and the security of food was transferred from the agricultural directorate to the new directorate general for health and consumers (SANCO) (Clergeau 2005). In addition, beginning in 1995...

... exchanges already exist: a woman can legally sell access to her uterus through surrogate motherhood, a man can sell his sperm, and most healthy individuals can sell their blood plasma. As Benjamin Hippen argues, moral opposition should not necessarily equate to legal prohibi- tion, because...